Corona Remedies IPO GMP 27% – Listing Update

The **Corona Remedies IPO**, a ₹655.37 crore public offering, is open for subscription until **December 10, 2025**. This is a pure **Offer for Sale (OFS)**, meaning the company itself will not receive any proceeds; all funds will go to the selling promoters and existing investors. Despite this, the IPO has seen an overwhelmingly strong response, positioning it for a potentially robust listing.

📋 Issue Snapshot and Strong Investor Demand

Corona Remedies is a specialist pharmaceutical company with a strong focus on the domestic market (96% of FY25 revenue is India-centric). It is known for its focus on **specialist doctors** (76% of prescriptions) and a portfolio of 71 brands across women’s healthcare, cardio-diabeto, and urology, making it one of the fastest-growing top 30 pharma companies in India.

📊 Subscription & Grey Market Premium (GMP) Analysis

Investor response has been exceptional, indicating high confidence in the company’s fundamentals. The IPO is already subscribed over **9.33 times** overall as of Day 2, largely driven by the **Non-Institutional Investor (NII)** segment, often a proxy for listing-gain appetite.

• **NII Subscription:** Subscribed over **27 times** (Exceptional demand from HNIs).
• **Retail Subscription:** Subscribed over **6.4 times** (Solid retail interest).
• **Corona Remedies IPO GMP:** Currently commanding a substantial premium of around **₹290 per share** (approx. **27.31%** over the upper price band). This robust GMP is a strong indicator of high listing expectations, often translating into a notable debut pop.

The subscription surge, coupled with the high GMP, places Corona Remedies as the most favored listing-gain candidate among the active mainboard IPOs.

⚖️ Financial Strengths and Valuation

Corona Remedies boasts strong financial metrics. Revenue grew by **16.3%** annually to **₹1,196.4 crore** in FY25, and net profit jumped **32.6%** to **₹149.4 crore** in the same period. Key positives include:

• **High Margins:** Gross margin is high (over 80%), and EBITDA margin improved to a strong **20.6%** in FY25.
• **Superior Growth:** The company’s sales growth of 16.3% CAGR (FY23-25) significantly outpaces the 9% growth of the overall Indian Pharmaceutical Market (IPM).
• **Strong Returns:** High Return on Equity (RoE) of **27.5%** and Return on Capital Employed (RoCE) of **47.9%** in FY25.
• **Low Leverage:** The balance sheet is healthy, operating with low net debt (net debt-to-equity is around 0.10x).

At the upper price band, the company is valued at a Price-to-Earnings (P/E) multiple of about **43.5 times** its FY25 earnings. This valuation is in line with the industry average of high-growth, branded generic players, suggesting the company’s strong growth and margins justify the pricing, but leaves moderate room for further P/E expansion post-listing.

⚠️ Key Risks for Long-Term Investors

Despite the strong debut potential, investors must note two main risks: **(1) The IPO is 100% OFS**; the company receives no expansion capital from the issue, relying instead on internal accruals and debt for future growth. **(2) Concentration Risk**: Over 70% of domestic sales come from a small set of “engine brands,” and sales are heavily concentrated in a few Western and Central Indian states. This regional and brand dependency poses a concentrated business risk.

The IPO is highly attractive for **listing gains** due to the strong GMP and subscription. Long-term investors with a high-risk appetite can consider holding, given the strong growth trajectory in the specialist pharma segment, particularly its focus on chronic therapies that provide sustained revenue streams.

Keywords: Corona Remedies IPO, Corona Remedies GMP, Corona Remedies Limited analysis, Offer for Sale IPO risks, Pharma IPO investment rationale, Corona Remedies valuation

***Disclaimer***

The information provided above is for informational and educational purposes only. Grey Market Premium (GMP) is an unofficial, unregulated indicator of market sentiment and should not be considered a recommendation to invest or a guaranteed listing price. All investors must conduct their own due diligence, consult with a certified financial advisor, and read the official Red Herring Prospectus (RHP) before making any investment decision. IPO investments are subject to market risks.